Replies to post #21592 on Cytodyn Inc (CYDY)

[Bulldog88]

Lol there has been absolutely nothing to suggest mono, or any other trial results for that matter, have been anything less than impressive. Sure, trials have been longer than many investors had anticipated or hoped for, but in the grand scheme of things, for a product in a biotech market like this it has been pretty quick. Not trying to “pump” here but i have yet to see anything negative results wise in 3 years invested. For me, a few months sp swing makes no difference. I’m here for the long haul and know exactly what we have. IMO, A lot of the sp volatility has to do with swing traders (expected) not concerned or even aware of the magnitude of this product. Doesn’t bother me one bit. If i was simply trading on TA, charts, or PRs I’d do the same. I’m invested for different reasons and have full confidence in its success.

[Saltz]

Bud, I’m not certain about a positive date, I’m optimistic about positive interim data but asked the question how far along are we in terms of having relevant patient population to release Interim Mono data? I know that Mono enrollment stalled out because all resources were put into completing Combo enrollment. So once again how many do we have enrolled and what is the impact of the increased standard dosage to 525ml. Obviously there is much riding on the Interim readout. If its not strong enough to convince the FDA to convert from investigational to a P3 Pivotal we will be stuck with a valuation based on Combo therapy. If it’s strong and we get the green light from the FDA to convert to the Pivotal Trial BP has to think seriously about making a play.